Literature DB >> 1300492

Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons.

P Mailleux1, J J Vanderhaeghen.   

Abstract

In the infant and adult human basal ganglia, the finding of mRNA exclusively in the striatal medium-sized neurons together with the detection of [3H]CP55,940 binding sites in the caudate-putamen, accumbens, substantia nigra pars reticulata and globus pallidus suggests cannabinoid receptor localization on the striatal intrinsic enkephalinergic and substance P-projecting neurons and on their nigral and pallidal terminals. However, the consistent finding of higher binding in the substantia nigra pars reticulata and medial part of the globus pallidus over its lateral segment suggests cannabinoid receptor enrichment on the striatal substance P neurons which express selectively the dopamine D1 receptor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1300492     DOI: 10.1016/0304-3940(92)90832-r

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  27 in total

1.  Neurodevelopmental liabilities of substance abuse.

Authors:  Tomas Palomo; Trevor Archer; Richard J Beninger; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

2.  Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor.

Authors:  M Glass; C C Felder
Journal:  J Neurosci       Date:  1997-07-15       Impact factor: 6.167

Review 3.  Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome.

Authors:  Didier Jutras-Aswad; Jennifer A DiNieri; Tibor Harkany; Yasmin L Hurd
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-02       Impact factor: 5.270

4.  Repeated administration of a synthetic cannabinoid receptor agonist differentially affects cortical and accumbal neuronal morphology in adolescent and adult rats.

Authors:  A F Carvalho; B A S Reyes; F Ramalhosa; N Sousa; E J Van Bockstaele
Journal:  Brain Struct Funct       Date:  2014-10-28       Impact factor: 3.270

Review 5.  Molecular imaging of levodopa-induced dyskinesias.

Authors:  Flavia Niccolini; Lorenzo Rocchi; Marios Politis
Journal:  Cell Mol Life Sci       Date:  2015-02-15       Impact factor: 9.261

6.  Inhibition of striatal dopamine release by CB1 receptor activation requires nonsynaptic communication involving GABA, H2O2, and KATP channels.

Authors:  Zsuzsanna Sidló; Patricia H Reggio; Margaret E Rice
Journal:  Neurochem Int       Date:  2007-07-22       Impact factor: 3.921

7.  The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats.

Authors:  Marco Bortolato; Gian Nicola Aru; Roberto Frau; Marco Orrù; Grant Christopher Luckey; Gianluca Boi; Gian Luigi Gessa
Journal:  Psychopharmacology (Berl)       Date:  2004-07-28       Impact factor: 4.530

8.  Cerebral glucose metabolism and D2/D3 receptor availability in young adults with cannabis dependence measured with positron emission tomography.

Authors:  Serge Sevy; Gwenn S Smith; Yilong Ma; Vijay Dhawan; Thomas Chaly; Peter B Kingsley; Sanjiv Kumra; Sherif Abdelmessih; David Eidelberg
Journal:  Psychopharmacology (Berl)       Date:  2008-02-13       Impact factor: 4.530

9.  Striatal CB1 and D2 receptors regulate expression of each other, CRIP1A and δ opioid systems.

Authors:  Lawrence C Blume; Caroline E Bass; Steven R Childers; George D Dalton; David C S Roberts; Jasmine M Richardson; Ruoyu Xiao; Dana E Selley; Allyn C Howlett
Journal:  J Neurochem       Date:  2013-01-31       Impact factor: 5.372

Review 10.  Short- and long-term consequences of prenatal exposure to the cannabinoid agonist WIN55,212-2 on rat glutamate transmission and cognitive functions.

Authors:  Luca Ferraro; M C Tomasini; S Beggiato; S Gaetani; T Cassano; V Cuomo; S Amoroso; S Tanganelli; T Antonelli
Journal:  J Neural Transm (Vienna)       Date:  2009-05-12       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.